To elucidate the specific mechanisms by which IPA sensitizes ICB therapy through CD8+ T cells, the research team conducted single-cell RNA sequencing (scRNA-seq), single-cell T cell receptor sequencing (scTCR-seq), and single-cell ATAC sequencing (scATAC-seq) analyses on CD8+ T cells from tumor-bearing mice. The gene discussed is CD8A; the disease is neoplasm.